Systemic therapy has switched from CMF (cyclophosphamide, methotrexate and 5-fluorouracil) to regimens containing anthracycline [4], routine searches for oestrogen and progesterone receptors has allowed for the introduction of tamoxifen, as well as identification of tumours positive to Her2/neu has enabled targeted therapy with trastuzumab [5], which was authorised in the European Union on August 28, 2000. This evidence concerns the gene ERBB2 and neoplasm.